GlassScriptPhysician profile
Timothy L Gard
NPI 1659375244
$3,057.19
in general payments reported to CMS, 2019-2025
24 companies · $330 in 2025
The $330 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $527 · 2020: $66.79 · 2021: $135 · 2022: $221 · 2023: $329 · 2024: $1,448 · 2025: $330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $1,200 · Food and Beverage: $907.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $1,200.00 |
| Food and Beverage | $906.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $1,263.40 | 2022-2025 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Regeneron Healthcare Solutions, INC. | $320.39 | 2019-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $265.75 | 2019-2023 | Vabysmo |
| Abbvie INC. | $186.09 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $149.66 | 2019-2024 | Cequa |
| Alcon Vision LLC | $107.19 | 2019-2025 | Tryptyr, Precision 1 |
| Allergan, INC. | $98.53 | 2019-2022 | |
| Astellas Pharma US INC | $87.81 | 2023-2025 | Izervay |
| Novartis Pharmaceuticals Corporation | $80.35 | 2019 | |
| Bausch & Lomb Americas INC. | $71.09 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Amgen INC. | $69.25 | 2024 | Tepezza |
| Horizon Therapeutics Plc | $69.19 | 2022-2023 | Tepezza |
| Kala Pharmaceuticals, INC. | $62.34 | 2019-2021 | |
| Thea Pharma INC. | $33.26 | 2024-2025 | Iyuzeh |
| Optos, INC. | $27.50 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $24.15 | 2019 | |
| Aerie Pharmaceuticals, INC. | $20.80 | 2019 | |
| Biogen, INC. | $19.76 | 2023 | |
| Oyster Point Pharma, INC. | $19.72 | 2024 | Tyrvaya |
| Mallinckrodt Hospital Products INC. | $18.27 | 2025 | Acthar |
| Johnson & Johnson Surgical Vision, INC. | $17.47 | 2019 | |
| Alimera Sciences, INC. | $16.77 | 2023 | Yutiq |
| Biohaven Pharmaceutical Holding Company LTD. | $15.14 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $13.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Gard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.